Search results
Fatima Cody Stanford
Research Area(s) / Expertise:
Job title: Associate Professor of Medicine and Pediatrics
Author
Added:
6 months ago
Source:
Radcliffe CVRM
A new pooled analysis suggests that measures of abdominal adiposity, such as waist-to-height ratio, are better predictors of clinical outcomes than body mass index (BMI) alone in patients with heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF). Obesity is highly prevalent in this patient population and is linked to an increased risk of mortality and disability.This…
View more
Added:
2 years ago
ECO 2024 — Dr Donna H Ryan (Pennington Biomedical Research Center, US) joins us to discuss the first sub-analysis of the landmark SELECT trial (NCT03574597, Novo Nordisk).In this study, investigators looked at long-term weight loss with semaglutide 2.4 mg compared to a placebo among 17,604 participants. In SELECT, at 208 weeks, semaglutide produced clinically significant weight loss compared to…
View more
Added:
9 months ago
ESC Congress 2025 - The SEMA-VR CardioLink-15 trial revealed that semaglutide may enhance endogenous progenitor cell-mediated vasculogenic repair processes.Dr Subodh Verma (University of Toronto, Toronto, CA) joins us to discuss the findings from the SEMA-VR CardioLink-15 trial. The study compared usual care with semaglutide, GLP-1RA for six months in 46 patients with either type 2 diabetes…
View more
Added:
5 months ago
Source:
Radcliffe CVRM
A new study has defined a metabolome-informed body mass index (metBMI) that more accurately reflects adiposity and cardiometabolic risk than the traditional BMI calculation.² The findings, published in Nature Medicine, suggest this multi-omic approach could help identify high-risk individuals whose metabolic dysfunction is not captured by conventional measures.¹MethodologyResearchers developed…
View more
e-SPACE CRM 2026 – Day Two
Start date:
Apr 11, 2026
Broadcast
e-SPACE CRM 2026 – Day One
Start date:
Apr 10, 2026
Broadcast
Added:
1 year ago
EASD 24 - We are joined by Dr Helen Coulhoun (University of Edinburgh, UK) to discuss the key findings of a prespecified analysis of the SELECT trial, which investigated the effectiveness of semaglutide in reducing major cardiac events in the presence of impaired kidney function in patients with overweight and obesity.Findings showed that participants in the study with reduced eGFR and/or…
View more
Added:
5 months ago
Source:
Radcliffe Cardiology
The primary drivers of heart failure (HF) have shifted significantly over the past 35 years, with metabolic conditions such as obesity and diabetes now playing a more prominent role than traditional risk factors like myocardial infarction (MI).¹˒² This finding comes from a large US-based study analysing national health trends.MethodologyResearchers conducted a retrospective analysis of data from…
View more
Added:
7 months ago
AHA Scientific Sessions 2025 - Dr Milton Packer (Baylor University Medical Center, US) joins us to discuss his novel unifying hypothesis that heart failure with preserved ejection fraction arises primarily from visceral adipose tissue dysfunction and altered adipokine signaling, rather than as a heterogeneous disorder driven by multiple comorbidities.Interview Questions:Can you explain the core…
View more